<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35164787</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1546-0096</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Pediatric rheumatology online journal</Title>
          <ISOAbbreviation>Pediatr Rheumatol Online J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Primary antiphospholipid syndrome in pediatrics: beyond thrombosis. Report of 32 cases and review of the evidence.</ArticleTitle>
        <Pagination>
          <StartPage>13</StartPage>
          <MedlinePgn>13</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">13</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12969-022-00673-y</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Describe the frequency of thrombotic and non-thrombotic clinical manifestations, laboratory, treatment and prognosis in patients with pediatric primary antiphospholipid syndrome.</AbstractText>
          <AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">A retrospective study was carried out in patients with a diagnosis of primary antiphospholipid antibody syndrome, under 16 years of age, under follow-up by the pediatric rheumatology service of the General Hospital, National Medical Center, La Raza, from January 2013 to December 2020. The antiphospholipid syndrome was defined when it met the laboratory criteria of the Sidney criteria and the presence of thrombosis or non-criteria manifestations of the disease (hematological, neurological, cutaneous, renal, cardiac or pulmonary). Demographic, clinical, laboratory, treatment, and prognosis data were collected.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We report 32 patients, 21 female (65%) and 11 male (35%), mean age 11.75 years, evolution time 16 weeks. Thrombosis 9 patients (28%), 1 arterial and 8 venous. Non-thrombotic manifestations; Hematologic: thrombocytopenia 22 patients (69%), autoimmune hemolytic anemia 13 (40%), Fisher-Evans syndrome 6 (19%), lupus anticoagulant with hypoprothrombinemia syndrome 2 (6%). Dermatological: livedo reticularis 20 (62%), skin ulcers 2 (6%), Raynaud's phenomenon 8 (25%). Neurological: epilepsy 1 (3%), migraine 3 (9%), chorea 1 (3%) and cognitive impairment 3 (9%). Renal in 4 (13%). Laboratory: prolonged aPTT 30 (93%), lupus anticoagulant 32 (100%), positive IgG anticardiolipin 20 (62%), positive IgM anticardiolipin 19 (60%). AntiB2GPI was performed in only 3 patients, being positive in all.</AbstractText>
          <AbstractText Label="TREATMENT" NlmCategory="METHODS">anticoagulation in patients with thrombosis, antiplatelet in 23 (72%), steroid 30 (94%), immunosuppressant 30 (94%) and rituximab 4 (12.5%). No deaths were reported.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The clinical characteristics of patients with pediatric primary antiphospholipid syndrome differ from those presented in adults, since non-thrombotic manifestations are more frequent in children, for which classification criteria that include these manifestations are necessary for a better characterization of the disease in pediatric population.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Torres-Jimenez</LastName>
            <ForeName>Alfonso-Ragnar</ForeName>
            <Initials>AR</Initials>
            <Identifier Source="ORCID">0000-0003-1070-5875</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Rheumatology, National Medical Center La Raza, IMSS, Vallejo y Jacarandas, colonia La Raza, Azcapotzalco, D.F. México CP, 02990, México City, México. tojadr@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ramirez-Nova</LastName>
            <ForeName>Virginia</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Rheumatology, National Medical Center La Raza, IMSS, Vallejo y Jacarandas, colonia La Raza, Azcapotzalco, D.F. México CP, 02990, México City, México.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cespedes-Cruz</LastName>
            <ForeName>Adriana Ivonne</ForeName>
            <Initials>AI</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Rheumatology, National Medical Center La Raza, IMSS, Vallejo y Jacarandas, colonia La Raza, Azcapotzalco, D.F. México CP, 02990, México City, México.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sanchez-Jara</LastName>
            <ForeName>Berenice</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Hematology, National Medical Center La Raza, IMSS, Mexico City, México.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Velazquez-Cruz</LastName>
            <ForeName>Alejandra</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Rheumatology, National Medical Center La Raza, IMSS, Vallejo y Jacarandas, colonia La Raza, Azcapotzalco, D.F. México CP, 02990, México City, México.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bekker-Méndez</LastName>
            <ForeName>Vilma Carolina</ForeName>
            <Initials>VC</Initials>
            <AffiliationInfo>
              <Affiliation>Research Unit in Immunology and Infectology, National Medical Center La Raza, IMSS, Mexico City, México.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guerra-Castillo</LastName>
            <ForeName>Francisco Xavier</ForeName>
            <Initials>FX</Initials>
            <AffiliationInfo>
              <Affiliation>Research Unit in Immunology and Infectology, National Medical Center La Raza, IMSS, Mexico City, México.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Pediatr Rheumatol Online J</MedlineTA>
        <NlmUniqueID>101248897</NlmUniqueID>
        <ISSNLinking>1546-0096</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016736" MajorTopicYN="N">Antiphospholipid Syndrome</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>15</Day>
          <Hour>5</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35164787</ArticleId>
        <ArticleId IdType="pmc">PMC8842521</ArticleId>
        <ArticleId IdType="doi">10.1186/s12969-022-00673-y</ArticleId>
        <ArticleId IdType="pii">10.1186/s12969-022-00673-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>JayakodyArachchillage D, Greaves M. The chequered history of the antiphospholipid syndrome. Br J Haematol. 2014;165(5):609–617. doi: 10.1111/bjh.12848.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.12848</ArticleId>
            <ArticleId IdType="pubmed">24684307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GR. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983;2(8361):1211–1214. doi: 10.1016/s0140-6736(83)91267-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(83)91267-9</ArticleId>
            <ArticleId IdType="pubmed">6139567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris EN. Syndrome of the black swan. Br J Rheumatol. 1987;26(5):324–326. doi: 10.1093/rheumatology/26.5.324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/26.5.324</ArticleId>
            <ArticleId IdType="pubmed">3664156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eby C. Antiphospholipid syndrome review. Clin Lab Med. 2009;29(2):305–319. doi: 10.1016/j.cll.2009.06.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cll.2009.06.001</ArticleId>
            <ArticleId IdType="pubmed">19665680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asherson RA, Cervera R. The antiphospholipid syndrome: a syndrome in evolution. Ann Rheum Dis. 1992;51(2):147–150. doi: 10.1136/ard.51.2.147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.51.2.147</ArticleId>
            <ArticleId IdType="pmc">PMC1005646</ArticleId>
            <ArticleId IdType="pubmed">1550393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asherson RA, Khamashta MA, Gil A, Vazquez JJ, Chan O, Baguley E, Hughes GR. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med. 1989;86(4):391–399. doi: 10.1016/0002-9343(89)90335-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0002-9343(89)90335-5</ArticleId>
            <ArticleId IdType="pubmed">2494884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mackworth-Young CG, Loizou S, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis. 1989;48(5):362–367. doi: 10.1136/ard.48.5.362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.48.5.362</ArticleId>
            <ArticleId IdType="pmc">PMC1003764</ArticleId>
            <ArticleId IdType="pubmed">2730164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, Outt HH, Harris EN, Vilardell-Torres M, Hughes GR. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989;68(6):366–374. doi: 10.1097/00005792-198911000-00004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005792-198911000-00004</ArticleId>
            <ArticleId IdType="pubmed">2509856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alarcón-Segovia D, Delezé M, Oria CV, Sánchez-Guerrero J, Gómez-Pacheco L, Cabiedes J, Fernández L, de PonceLeón S. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Med (Baltimore) 1989;68(6):353–65. doi: 10.1097/00005792-198911000-00003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005792-198911000-00003</ArticleId>
            <ArticleId IdType="pubmed">2811661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Font J, López-Soto A, Cervera R, Balasch J, Pallarés L, Navarro M, Bosch X, Ingelmo M. The 'primary' antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients. Autoimmunity. 1991;9(1):69–75. doi: 10.3109/08916939108997126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08916939108997126</ArticleId>
            <ArticleId IdType="pubmed">1669849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alarcón-Segovia D, Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum. 1992;21(5):275–286. doi: 10.1016/0049-0172(92)90021-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0049-0172(92)90021-5</ArticleId>
            <ArticleId IdType="pubmed">1604324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309–1311. doi: 10.1002/1529-0131(199907)42:7&lt;1309::AID-ANR1&gt;3.0.CO;2-F.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1529-0131(199907)42:7&lt;1309::AID-ANR1&gt;3.0.CO;2-F</ArticleId>
            <ArticleId IdType="pubmed">10403256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DEGroot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost. 2006;4(2):295–306. doi: 10.1111/j.1538-7836.2006.01753.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId>
            <ArticleId IdType="pubmed">16420554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sciascia S, Amigo MC, Roccatello D, Khamashta M. Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances. Nat Rev Rheumatol. 2017;13(9):548–560. doi: 10.1038/nrrheum.2017.124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrrheum.2017.124</ArticleId>
            <ArticleId IdType="pubmed">28769114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman B, Kenet G, Koné-Paut I, Lahdenne P, Marks SD, McCann L, Pilkington CA, Ravelli A, van Royen-Kerkhof A, Uziel Y, Vastert SJ, Wulffraat NM, Ozen S, Brogan P, Kamphuis S, Beresford MW. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 2017;76(10):1637–1641. doi: 10.1136/annrheumdis-2016-211001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2016-211001</ArticleId>
            <ArticleId IdType="pubmed">28473426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danowski A, de Azevedo MN, de Souza Papi JA, Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009;36(6):1195–1199. doi: 10.3899/jrheum.081194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.081194</ArticleId>
            <ArticleId IdType="pubmed">19447935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. Blood Transfus. 2011;9(2):120–38. doi: 10.2450/2010.0066-10.Epub2010Oct25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2450/2010.0066-10.Epub2010Oct25</ArticleId>
            <ArticleId IdType="pmc">PMC3096855</ArticleId>
            <ArticleId IdType="pubmed">21084000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Zeinah G, Oromendia C, DeSancho MT. Thrombotic risk factors in patients with antiphospholipid syndrome: a single center experience. J Thromb Thrombolysis. 2019;48(2):233–239. doi: 10.1007/s11239-019-01836-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11239-019-01836-7</ArticleId>
            <ArticleId IdType="pubmed">30835035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Branchford BR, Mahajerin A, Raffini L, Chalmers E, van Ommen CH, Chan AKC, Goldenberg NA. Subcommittee on Pediatric/Neonatal Hemostasis and Thrombosis. Recommendations for standardized risk factor definitions in pediatric hospital-acquired venous thromboembolism to inform future prevention trials: communication from the SSC of the ISTH. J Thromb Haemost. 2017;15(11):2274–2278. doi: 10.1111/jth.13848.Epub2017Oct13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jth.13848.Epub2017Oct13</ArticleId>
            <ArticleId IdType="pubmed">29027741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parasuraman S, Goldhaber SZ. Venous thromboembolism in children. Circulation. 2006;113(2):e12–e16. doi: 10.1161/CIRCULATIONAHA.105.583773.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.583773</ArticleId>
            <ArticleId IdType="pubmed">16418440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarango C, Palumbo JS. Antiphospholipid syndrome in pediatric patients. Curr Opin Hematol. 2019;26(5):366–371. doi: 10.1097/MOH.0000000000000523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MOH.0000000000000523</ArticleId>
            <ArticleId IdType="pubmed">31348049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madison JA, Zuo Y, Knight JS. Pediatric antiphospholipid syndrome. Eur J Rheumatol. 2019;7(Suppl 1):1–10. doi: 10.5152/eurjrheum.2019.19160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5152/eurjrheum.2019.19160</ArticleId>
            <ArticleId IdType="pmc">PMC7004270</ArticleId>
            <ArticleId IdType="pubmed">31804173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meroni PL, Argolini LM, Pontikaki I. What is known about pediatric antiphospholipid syndrome? Expert Rev Hematol. 2016;9(10):977–985. doi: 10.1080/17474086.2016.1235969.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17474086.2016.1235969</ArticleId>
            <ArticleId IdType="pubmed">27615277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rumsey DG, Myones B, Massicotte P. Diagnosis and treatment of antiphospholipid syndrome in childhood: A review. Blood Cells Mol Dis. 2017;67:34–40. doi: 10.1016/j.bcmd.2017.02.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcmd.2017.02.009</ArticleId>
            <ArticleId IdType="pubmed">28283251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cimaz R, Descloux E. Pediatric antiphospholipid syndrome. Rheum Dis Clin North Am. 2006;32(3):553–573. doi: 10.1016/j.rdc.2006.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rdc.2006.05.005</ArticleId>
            <ArticleId IdType="pubmed">16880084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravelli A, Martini A. Antiphospholipid syndrome in pediatrics. Rheum Dis Clin North Am. 2007;33(3):499–523. doi: 10.1016/j.rdc.2007.07.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rdc.2007.07.001</ArticleId>
            <ArticleId IdType="pubmed">17936175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avcin T, Cimaz R, Silverman ED, Cervera R, Gattorno M, Garay S, Berkun Y, Sztajnbok FR, Silva CA, Campos LM, Saad-Magalhaes C, Rigante D, Ravelli A, Martini A, Rozman B, Meroni PL. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008;122(5):e1100–e1107. doi: 10.1542/peds.2008-1209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2008-1209</ArticleId>
            <ArticleId IdType="pubmed">18955411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma J, Song H, Wei M, He Y. Clinical characteristics and thrombosis outcomes of paediatric antiphospholipid syndrome: analysis of 58 patients. Clin Rheumatol. 2018;37(5):1295–1303. doi: 10.1007/s10067-017-3776-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-017-3776-5</ArticleId>
            <ArticleId IdType="pubmed">28748509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nageswara Rao AA, Elwood K, Kaur D, Warad DM, Rodriguez V. A retrospective review of pediatric antiphospholipid syndrome and thrombosis outcomes. Blood Coagul Fibrinolysis. 2017;28(3):205–210. doi: 10.1097/MBC.0000000000000576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MBC.0000000000000576</ArticleId>
            <ArticleId IdType="pubmed">27428014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avcin T. PReS13-SPK-1592: Pediatric aspects of antiphospholipid syndrome. Pediatr Rheumatol Online J. 2013;11(Suppl 2):I13. Published 2013 Dec 5. 10.1186/1546-0096-11-S2-I13.</Citation>
        </Reference>
        <Reference>
          <Citation>Tassies D, Reverter J. Hematologic Abnormalities in the Antiphospholipid Syndrome. Curr Rheumatol Rev. 2010;6:55. doi: 10.2174/157339710790827740.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/157339710790827740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uthman I, Godeau B, Taher A, Khamashta M. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev. 2008;22(4):187–194. doi: 10.1016/j.blre.2008.03.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.blre.2008.03.005</ArticleId>
            <ArticleId IdType="pubmed">18417261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pilania RK, Suri D, Jindal AK, Kumar N, Sharma A, Sharma P, Guleria S, Rawat A, Ahluwalia J, Singh S. Lupus anticoagulant hypoprothrombinemia syndrome associated with systemic lupus erythematosus in children: report of two cases and systematic review of the literature. Rheumatol Int. 2018;38(10):1933–1940. doi: 10.1007/s00296-018-4127-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-018-4127-9</ArticleId>
            <ArticleId IdType="pubmed">30099593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazodier K, Arnaud L, Mathian A, Costedoat-Chalumeau N, Haroche J, Frances C, Harlé JR, Pernod G, Lespessailles E, Gaudin P, Charlanne H, Hachulla E, Niaudet P, Piette JC, Amoura Z. Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature. Medicine (Baltimore) 2012;91(5):251–260. doi: 10.1097/MD.0b013e31826b971f.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0b013e31826b971f</ArticleId>
            <ArticleId IdType="pubmed">22932789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frances C. Dermatological manifestations of Hughes' antiphospholipid antibody syndrome. Lupus. 2010;19(9):1071–1077. doi: 10.1177/0961203310370343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0961203310370343</ArticleId>
            <ArticleId IdType="pubmed">20693200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muscal E, Brey RL. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus. 2010;19(4):406–411. doi: 10.1177/0961203309360808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0961203309360808</ArticleId>
            <ArticleId IdType="pmc">PMC2980850</ArticleId>
            <ArticleId IdType="pubmed">20353978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graf J. Central Nervous System Manifestations of Antiphospholipid Syndrome. Rheum Dis Clin North Am. 2017;43(4):547–560. doi: 10.1016/j.rdc.2017.06.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rdc.2017.06.004</ArticleId>
            <ArticleId IdType="pubmed">29061241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 2003;42(2):200–213. doi: 10.1093/rheumatology/keg080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/keg080</ArticleId>
            <ArticleId IdType="pubmed">12595612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noureldine M, Harifi G, Haydar A, et al. AB0487 Antiphospholipid Syndrome and Epilepsy: Where Do We Stand? Ann Rheum Dis. 2016;75:1072. https://ard.bmj.com/content/75/Suppl_2/1072.2.info.</Citation>
        </Reference>
        <Reference>
          <Citation>Erkan D, Lockshin MD. Non-criteria manifestations of antiphospholipid syndrome. Lupus. 2010;19(4):424–427. doi: 10.1177/0961203309360545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0961203309360545</ArticleId>
            <ArticleId IdType="pubmed">20353981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tenedios F, Erkan D, Lockshin MD. Cardiac manifestations in the antiphospholipid syndrome. Rheum Dis Clin North Am. 2006;32(3):491–507. doi: 10.1016/j.rdc.2006.05.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rdc.2006.05.008</ArticleId>
            <ArticleId IdType="pubmed">16880080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ford HJ, Roubey RA. Pulmonary manifestations of the antiphospholipid antibody syndrome. Clin Chest Med. 2010;31(3):537–545. doi: 10.1016/j.ccm.2010.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccm.2010.05.005</ArticleId>
            <ArticleId IdType="pubmed">20692545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Espinosa G, Cervera R, Font J, Asherson RA. The lung in the antiphospholipid syndrome. Ann Rheum Dis. 2002;61(3):195–198. doi: 10.1136/ard.61.3.195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.61.3.195</ArticleId>
            <ArticleId IdType="pmc">PMC1754043</ArticleId>
            <ArticleId IdType="pubmed">11830421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turrent-Carriles A, Herrera-Félix JP, Amigo MC. Renal Involvement in Antiphospholipid Syndrome. Front Immunol. 2018;17(9):1008. doi: 10.3389/fimmu.2018.01008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.01008</ArticleId>
            <ArticleId IdType="pmc">PMC5966534</ArticleId>
            <ArticleId IdType="pubmed">29867982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sciascia S, Cuadrado MJ, Khamashta M, Roccatello D. Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol. 2014;10(5):279–289. doi: 10.1038/nrneph.2014.38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneph.2014.38</ArticleId>
            <ArticleId IdType="pubmed">24642799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tektonidou MG. Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. Front Immunol. 2018;31(9):1181. doi: 10.3389/fimmu.2018.01181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.01181</ArticleId>
            <ArticleId IdType="pmc">PMC5990608</ArticleId>
            <ArticleId IdType="pubmed">29904380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tebo AE. Laboratory Evaluation of Antiphospholipid Syndrome: An Update on Autoantibody Testing. Clin Lab Med. 2019;39(4):553–565. doi: 10.1016/j.cll.2019.07.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cll.2019.07.004</ArticleId>
            <ArticleId IdType="pubmed">31668269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aguiar CL, Soybilgic A, Avcin T, Myones BL. Pediatric antiphospholipid syndrome. Curr Rheumatol Rep. 2015;17(4):27. doi: 10.1007/s11926-015-0504-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11926-015-0504-5</ArticleId>
            <ArticleId IdType="pubmed">25854492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abreu MM, Danowski A, Wahl DG, Amigo MC, Tektonidou M, Pacheco MS, Fleming N, Domingues V, Sciascia S, Lyra JO, Petri M, Khamashta M, Levy RA. The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401–414. doi: 10.1016/j.autrev.2015.01.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2015.01.002</ArticleId>
            <ArticleId IdType="pubmed">25641203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbhaiya M, Zuily S, Ahmadzadeh Y, Amigo MC, Avcin T, Bertolaccini ML, Branch DW, de Jesus G, Devreese KMJ, Frances C, Garcia D, Guillemin F, Levine SR, Levy RA, Lockshin MD, Ortel TL, Seshan SV, Tektonidou M, Wahl D, Willis R, Naden R, Costenbader K, Erkan D, New APS Classification Criteria Collaborators  Development of a new international antiphospholipid syndrome classification criteria phase i/ii report: generation and reduction of candidate criteria. Arthritis Care Res (Hoboken) 2021;73(10):1490–1501. doi: 10.1002/acr.24520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acr.24520</ArticleId>
            <ArticleId IdType="pubmed">33253499</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
